In mice with melanoma, creatine supplementation increases the number and activity of type 1 dendritic cells in tumors and decreases tumor size.
See the scientific wording
Creatine supplementation in a syngeneic mouse melanoma model (B16-OVA) increases the abundance and activation of type 1 dendritic cells (cDC1s) in tumors and reduces tumor growth.
Correlational — new studies may shift this
ObservationalOne moderate-quality study links this claim to the outcome, but causation is not established.
What the research says
1 study reviewedSupporting (1)
Creatine uptake promotes dendritic cell activation and enhances antitumor immunity
Cohort StudyHuman2026
In mice with skin cancer, giving creatine helped immune cells called cDC1s work better and grow in number inside tumors, which made the tumors grow slower. The same thing happened with human immune cells in the lab.
Contradicting (0)
No contradicting studies found yet
That doesn't mean it's settled — it just means no study has tested the opposite.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
Immune cells in the tumor take up creatine from the blood, convert it into a stored energy form, and use that energy to stay active and send strong signals. This keeps their energy levels high, allowing them to turn on key inflammatory pathways that make them better at alerting killer immune cells to attack the tumor. As a result, more killer cells enter the tumor and stop it from growing.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting study
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
In mice with melanoma, creatine supplementation increases the number and activity of type 1 dendritic cells in tumors and decreases tumor size.
Mechanism
1 studyTumor-fighting immune cells take in creatine to keep their energy high, which lets them send stronger signals to activate killer T cells. These activated T cells then enter the tumor and stop it from growing.
Immune cells in the tumor take up creatine from the blood, convert it into a stored energy form, and use that energy to stay active and send strong signals. This keeps their energy levels high, allowing them to turn on key inflammatory pathways that make them better at alerting killer immune cells to attack the tumor. As a result, more killer cells enter the tumor and stop it from growing.
Dendritic cells increase expression of the creatine transporter on their surface in response to inflammatory signals from the tumor microenvironment
Creatine enters dendritic cells through the transporter and is converted into phosphocreatine, forming a high-energy reservoir
The phosphocreatine system maintains intracellular ATP levels during periods of high energy demand, preventing depletion and sustaining low AMP:ATP and ADP:ATP ratios
Sustained ATP levels enable continuous activation of the NF-κB signaling pathway, including phosphorylation of IKKβ, IκBα, and p65, and nuclear translocation of p65
Activated NF-κB increases transcription of genes encoding costimulatory molecules and proinflammatory cytokines, enhancing dendritic cell maturation and antigen presentation
Activated dendritic cells prime tumor-specific CD8+ T cells, increasing their proliferation, cytokine production, and expression of activation markers
Priming of CD8+ T cells leads to increased infiltration and activation of tumor-specific T cells within the tumor, resulting in suppression of tumor growth
Evidence from Studies
Supporting (1)
Community contributions welcome
Creatine uptake promotes dendritic cell activation and enhances antitumor immunity
In mice with skin cancer, giving creatine helped immune cells called cDC1s work better and grow in number inside tumors, which made the tumors grow slower. The same thing happened with human immune cells in the lab.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review of Creatine Supplementation Effects on cDC1s and Tumor Growth in Preclinical Melanoma Models
Systematic review and meta-analysis of all published animal studies using syngeneic melanoma models (e.g., B16-OVA) with creatine supplementation versus control, measuring cDC1 abundance, activation markers, and tumor volume over time.
Randomized Controlled Trial of Creatine vs Placebo on cDC1s and Tumor Growth in B16-OVA Melanoma-Bearing Mice
Randomized, blinded, placebo-controlled trial in C57BL/6 mice bearing B16-OVA tumors, with creatine administered orally or via injection, measuring cDC1 frequency (flow cytometry), activation markers (CD80, CD86, MHC-II), and tumor volume over 14–21 days.
Cohort Study of Creatine Dose-Response Effects on cDC1s and Tumor Progression in B16-OVA Mice
Prospective cohort of B16-OVA tumor-bearing mice assigned to incremental creatine doses (0, 0.5, 1.0, 2.0 g/kg/day) with longitudinal tracking of cDC1 populations and tumor size over 21 days.
In Vitro Study of Creatine on Dendritic Cell Activation and Antigen Presentation in Murine cDC1 Cultures
Isolated murine cDC1s exposed to creatine (0–10 mM) in culture, measuring surface marker expression, cytokine secretion, and T-cell priming capacity compared to untreated controls.
Pilot Animal Study Assessing Creatine Effects on Tumor Immunity in B16-OVA Melanoma
Small n (n=5–8 per group) pilot study in B16-OVA mice with creatine supplementation, measuring tumor volume, cDC1 frequency, and splenic immune cell profiles without randomization or blinding.